Abstract
Probiotics are live microorganisms that confer a health benefit on the host. Duolac-Gold is a mixture of seven probiotic bacteria containing three species of Bifidobacteria, two species of Lactobacillus, and Streptococcus thermophilus. The aim of this study was to assess the anti-inflammatory effects of Duolac-Gold in an inflammatory bowel disease (IBD) mouse model. IBD was induced by administering 1.5% dextran sulfate sodium (DSS) for 10 days. After induction of DSS-induced colitis, Duolac-Gold was orally administered at three different concentrations. Interestingly, Duolac-Gold treatment accelerated IBD healing, and anti-inflammatory activity was assessed by weight loss, length of the colon, and a microscopic damage score by histology. The expression of inflammatory related cytokines was measured in colon tissues and serum. Of these cytokines, the expression of interleukin-6 decreased remarkably after Duolac-Gold treatment. Taken together, these results suggest that Duolac-Gold treatment is effective in IBD healing by regulating IL-6.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Bai, A.P. and Ouyang, Q. (2006) Probiotics and inflammatory bowel diseases. Postgrad. Med. J., 82, 376–382.
Stein, J., Hartmann, F. and Dignass, A.U. (2010) Diagnosis and management of iron deficiency anemia in patients with IBD. Nat. Rev. Gastroenterol. Hepatol., 7, 599–610.
Kaser, A., Zeissig, S. and Blumberg, R.S. (2010) Inflammatory bowel disease. Annu. Rev. Immunol., 28, 573–621.
Rogler, G. and Andus, T. (1998) Cytokines in inflammatory bowel disease. World J. Surg., 22, 382–389.
Atreya, R., Mudter, J., Finotto, S., Mullberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., Strand, D., Czaja, J., Schlaak, J.F., Lehr, H.A., Autschbach, F., Schürmann, G., Nishimoto, N., Yoshizaki, K., Ito, H., Kishimoto, T., Galle, P.R., Rose-John, S. and Neurath, M.F. (2000) Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat. Med., 6, 583–588.
Shen, D., Liu, C., Xu, R. and Zhang, F. (2012) Human gut microbiota: dysbiosis and manipulation. Front. Cell. Infect. Microbiol., 2, 123.
de Vos, W.M. and de Vos, E.A. (2012) Role of the intestinal microbiome in health and disease: from correlation to causation. Nutr. Rev., 70 Suppl 1, S45–56.
Abraham, C. and Medzhitov, R. (2011) Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology, 140, 1729–1737.
Bien, J., Palagani, V. and Bozko, P. (2013) The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Ther. Adv. Gastroenterol., 6, 53–68.
Walker, A.W. and Lawley, T.D. (2013) Therapeutic modulation of intestinal dysbiosis. Pharmacol. Res., 69, 75–86.
Uccello, M., Malaguarnera, G., Basile, F., D’Agata, V., Malaguarnera, M., Bertino, G., Vacante, M., Drago, F. and Biondi, A. (2012) Potential role of probiotics on colorectal cancer prevention. BMC Surg., 12 Suppl 1, S35.
Ouwehand, A.C., Salminen, S. and Isolauri, E. (2002) Probiotics: an overview of beneficial effects. Antonie Va n Leeuwen-hoek, 82, 279–289.
Salminen, S., Bouley, C., Boutron-Ruault, M.C., Cummings, J.H., Franck, A., Gibson, G.R., Isolauri, E., Moreau, M.C., Roberfroid, M. and Rowland, I. (1998) Functional food science and gastrointestinal physiology and function. B r. J. Nutr., 80 Suppl 1, S147–171.
Sang, L.X., Chang, B., Zhang, W.L., Wu, X.M., Li, X.H. and Jiang, M. (2010) Remission induction and maintenance effect of probiotics on ulcerative colitis: A meta-analysis. World J. Gastroenterol., 16, 1908–1915.
Lee, J.S., Chung, M.J. and Seo, J.G. (2013) In Vitro Evaluation of Antimicrobial Activity of Lactic Acid Bacteria against Clostridium difficile. Toxicol. Res., 29, 99–106.
Miyauchi, E., Ogita, T., Miyamoto, J., Kawamoto, S., Morita, H., Ohno, H., Suzuki, T. and Tanabe, S. (2013) Bifidobacterium longum alleviates dextran sulfate sodium-induced colitis by suppressing IL-17A response: involvement of intestinal epithelial costimulatory molecules. PLoS One, 8, e79735.
Matsumoto, Y. (2005) New approach to immunotherapy against organ-specific autoimmune diseases with T cell receptor and chemokine receptor DNA vaccines. Curr. Drug Targets Immune Endocr. Metab. Disord., 5, 73–77.
Wang, W., Chen, L., Zhou, R., Wang, X., Song, L., Huang, S., Wang, G. and Xia, B. (2014) Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J. Clin. Microbiol., 52, 398–406.
MacPherson, B.R. and Pfeiffer, C.J. (1978) Experimental production of diffuse colitis in rats. Digestion, 17, 135–150.
Strober, W., Fuss, I.J. and Blumberg, R.S. (2002) The immunology of mucosal models of inflammation. Annu. Rev. Immunol., 20, 495–549.
Okayasu, I., Hatakeyama, S., Yamada, M., Ohkusa, T., Ina-gaki, Y. and Nakaya, R. (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology, 98, 694–702.
Hyun, E., Andrade-Gordon, P., Steinhoff, M. and Vergnolle, N. (2008) Protease-activated receptor-2 activation: a major actor in intestinal inflammation. Gut, 57, 1222–1229.
Baumgart, D.C. and Sandborn, W.J. (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet, 369, 1641–1657.
Cooper, H.S., Murthy, S.N., Shah, R.S. and Sedergran, D.J. (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest., 69, 238–249.
Hedger, M.P. and Meinhardt, A. (2003) Cytokines and the immune-testicular axis. J. Reprod. Immunol., 58, 1–26.
Eming, S.A., Kaufmann, J., Löhrer, R. and Krieg, T. (2007) [Chronic wounds. Novel approaches in research and therapy]. Hautarzt, 58, 939–944.
Guha, M., O’Connell, M.A., Pawlinski, R., Hollis, A., McGovern, P., Yan, S.F., Stern, D. and Mackman, N. (2001) Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood, 98, 1429–1439.
D’Aiuto, F., Parkar, M., Brett, P.M., Ready, D. and Tonetti, M.S. (2004) Gene polymorphisms in pro-inflammatory cytokines are associated with systemic inflammation in patients with severe periodontal infections. Cytokine, 28, 29–34.
Cronstein, B.N. and Terkeltaub, R. (2006) Interleukin-6 and chronic inflammation. Arthritis Res. Ther., 8 Suppl 1, S3.
Dieleman, L. and Hoentjen, F. (2012) [Probiotics have a limited role in the treatment of inflammatory bowel disease]. Ned. Tijdschr. Geneeskd., 156, A5206.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Yoon, H., Yoon, YS., Kim, MS. et al. A Probiotic Preparation Duolac-Gold Ameliorates Dextran Sulphate Sodium-induced Mouse Colitis by Downregulating the Expression of IL-6. Toxicol Res. 30, 27–32 (2014). https://doi.org/10.5487/TR.2014.30.1.027
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.5487/TR.2014.30.1.027